OPKO has also made a variety of strategic investments and partnerships, in addition to protecting many patents. OPKO owns rights to leading preclinical candidate SR-3306 and related molecule compounds that could be the first drug to protect the brain from Parkinson’s, MS, ALS and AD. OPKO acquired rights from a Taiwan company for vaccines against influenza and other viral infections.
OPKO owns global rights to heparin-derived oligosaccharide for asthma and COPD.
What is also interesting is that both OPKO and Teva invested in Cocrystal Discovery, a privately held biopharmaceutical company focused on the discovery and development of novel small molecule antiviral therapeutics tailored for the treatment of serious and chronic viral diseases. It is currently developing oral, small molecule, antiviral therapeutics for Hepatitis C and influenza. OPKO has a strategic investment in Fabrus, a privately held company with next generation therapeutic antibody drug discovery. OPKO is aligned with Neovasc that is another private company developing and marketing various treatments for refractory angina and cardiac reconstruction. OPKO is strategically invested in Biozone whereas OPKO now holds a world-wide license for the development and commercialization of ophthalmology and other therapeutic fields. OPKO is also aligned with Teraro, Sorrento Therapeutics and ChromaDex Corporation for other products.
In 2010 OPKO out-licensed Rolapitant for the treatment of nausea and vomiting due to cancer treatment. Over 1000 patients have been evaluated in phases 1 & 2, with great results, and phase 3 results are expected in 2013. OPKO would be entitled to payments up to $121M and double digit tiered royalties.